224 related articles for article (PubMed ID: 21705045)
1. Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information.
Zaytoun OM; Kattan MW; Moussa AS; Li J; Yu C; Jones JS
Urology; 2011 Aug; 78(2):392-8. PubMed ID: 21705045
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis of isolated high-grade prostatic intra-epithelial neoplasia: proposal of a nomogram for the prediction of cancer detection at saturation re-biopsy.
Roscigno M; Scattoni V; Freschi M; Abdollah F; Maccagnano C; Galosi A; Lacetera V; Montironi R; Muzzonigro G; Deho F; Deiana G; Belussi D; Chinaglia D; Montorsi F; Da Pozzo LF
BJU Int; 2012 May; 109(9):1329-34. PubMed ID: 21895935
[TBL] [Abstract][Full Text] [Related]
3. Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients.
Suzuki H; Komiya A; Kamiya N; Imamoto T; Kawamura K; Miura J; Suzuki N; Nakatsu H; Hata A; Ichikawa T
Urology; 2006 Jan; 67(1):131-6. PubMed ID: 16413348
[TBL] [Abstract][Full Text] [Related]
4. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.
Kawamura K; Suzuki H; Kamiya N; Imamoto T; Yano M; Miura J; Shimbo M; Suzuki N; Nakatsu H; Ichikawa T
Int J Urol; 2008 Jul; 15(7):598-603. PubMed ID: 18462353
[TBL] [Abstract][Full Text] [Related]
5. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
Garzotto M; Hudson RG; Peters L; Hsieh YC; Barrera E; Mori M; Beer TM; Klein T
Cancer; 2003 Oct; 98(7):1417-22. PubMed ID: 14508828
[TBL] [Abstract][Full Text] [Related]
6. Assessing individual risk for prostate cancer.
Nam RK; Toi A; Klotz LH; Trachtenberg J; Jewett MA; Appu S; Loblaw DA; Sugar L; Narod SA; Kattan MW
J Clin Oncol; 2007 Aug; 25(24):3582-8. PubMed ID: 17704405
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
8. History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.
Kawakami S; Koga F; Fujii Y; Saito K; Yamamoto S; Tatokoro M; Yonese J; Kageyama Y; Fukui I; Kihara K
Int J Urol; 2008 Dec; 15(12):1055-60. PubMed ID: 19054174
[TBL] [Abstract][Full Text] [Related]
9. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.
Nakanishi H; Wang X; Ochiai A; Trpkov K; Yilmaz A; Donnelly JB; Davis JW; Troncoso P; Babaian RJ
Cancer; 2007 Dec; 110(11):2441-7. PubMed ID: 17932909
[TBL] [Abstract][Full Text] [Related]
10. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer.
Yanke BV; Gonen M; Scardino PT; Kattan MW
J Urol; 2005 Feb; 173(2):421-4. PubMed ID: 15643192
[TBL] [Abstract][Full Text] [Related]
11. A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling.
Moussa AS; Kattan MW; Berglund R; Yu C; Fareed K; Jones JS
BJU Int; 2010 Feb; 105(3):352-8. PubMed ID: 19681898
[TBL] [Abstract][Full Text] [Related]
12. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.
Chun FK; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Stillebroer AB; van Gils MP; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Haese A
Eur Urol; 2009 Oct; 56(4):659-67. PubMed ID: 19304372
[TBL] [Abstract][Full Text] [Related]
14. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy.
Kawakami S; Numao N; Okubo Y; Koga F; Yamamoto S; Saito K; Fujii Y; Yonese J; Masuda H; Kihara K; Fukui I
Eur Urol; 2008 Sep; 54(3):601-11. PubMed ID: 18207312
[TBL] [Abstract][Full Text] [Related]
15. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
[TBL] [Abstract][Full Text] [Related]
16. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of prostate-specific antigen mass ratio for prediction of prostate cancer detection on a repeated prostate biopsy.
Lee WK; Lee S; Hong SK; Lee SE; Choi WS; Byun SS
Int Braz J Urol; 2014; 40(4):484-92. PubMed ID: 25251953
[TBL] [Abstract][Full Text] [Related]
18. Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer.
Nam RK; Toi A; Klotz LH; Trachtenberg J; Jewett MA; Loblaw A; Pond GR; Emami M; Sugar L; Sweet J; Narod SA
Can J Urol; 2006 Apr; 13 Suppl 2():2-10. PubMed ID: 16672122
[TBL] [Abstract][Full Text] [Related]
19. Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy.
Lughezzani G; Lazzeri M; Larcher A; Lista G; Scattoni V; Cestari A; Buffi NM; Bini V; Guazzoni G
J Urol; 2012 Oct; 188(4):1144-50. PubMed ID: 22901589
[TBL] [Abstract][Full Text] [Related]
20. Development and external validation of an extended 10-core biopsy nomogram.
Chun FK; Briganti A; Graefen M; Montorsi F; Porter C; Scattoni V; Gallina A; Walz J; Haese A; Steuber T; Erbersdobler A; Schlomm T; Ahyai SA; Currlin E; Valiquette L; Heinzer H; Rigatti P; Huland H; Karakiewicz PI
Eur Urol; 2007 Aug; 52(2):436-44. PubMed ID: 17010505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
